Navigation Links
NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
Date:12/22/2010

ROCKVILLE, Md., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle (VLP) vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.  This vaccine candidate has been created with technology that Novavax has licensed exclusively from the University of Massachusetts Medical School.  

The publication describes the production and testing of a novel RSV VLP vaccine candidate. Immunization with this genetically engineered RSV VLP vaccine stimulated immune response against key vaccine targets, the RSV G attachment and RSV F fusion proteins. The antibody responses achieved with this vaccine candidate were equal to or better than levels resulting from infection with live RSV. This RSV G+F VLP vaccine stimulated both anti-G and anti-F protein serum antibodies typical of a more Th1-biased response characteristic of natural infection with RSV.  When challenged with live RSV, animals immunized with RSV VLPs were completely protected from replication of the virus in the lungs and showed no signs of enhanced respiratory disease.

"This study indicates that immunization with a VLP vaccine results in functional and protective immune responses against RSV.  Induction of such functional, protective immunity has been a key challenge in RSV vaccine development.  RSV is the leading global cause of infant and childhood respiratory disease, and these encouraging preclinical safety and efficacy data suggest that an RSV VLP vaccine is a promising approach and should be developed further," said Greg Glenn, M.D., Novavax's Chief Scientific Officer.

About Respiratory Syncytial Virus

RS
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
2. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
3. NOVAVAX Elects Richard H. Douglas to its Board of Directors
4. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
5. Novavax Announces Manufacturing Management Appointments
6. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
7. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
8. NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... rate of HIV infection and the number of deaths due ... positive rate across the globe. It has been estimated that ... 1.5 in 2013, with the rates for children being even ... the infection rates has been the improved access to antiretroviral ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
Breaking Biology Technology:Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... ON , Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences ... financial results for the second quarter of fiscal 2010, ended ... numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., ... during the second quarter," said David Allan , Chairman ...
... , DENVER and NEW ORLEANS , Feb. ... worldwide developer and marketer of diagnostic test kits, and Tulane ... to combat viral hemorrhagic fever (VHF), an effort that will generate ... the life of the contract. , The National Institutes of ...
... , Feb. 8 Neurocrine Biosciences, Inc. (Nasdaq: ... Ph.D. to its Board of Directors effective immediately. He is the ... Executive Chairman of Biogen Idec, Inc. , "We are very pleased ... said Joseph A. Mollica , Ph.D., Chairman of the Board ...
Cached Biology Technology:YM BioSciences reports second quarter 2010 operational and financial results 2YM BioSciences reports second quarter 2010 operational and financial results 3YM BioSciences reports second quarter 2010 operational and financial results 4YM BioSciences reports second quarter 2010 operational and financial results 5YM BioSciences reports second quarter 2010 operational and financial results 6YM BioSciences reports second quarter 2010 operational and financial results 7YM BioSciences reports second quarter 2010 operational and financial results 8YM BioSciences reports second quarter 2010 operational and financial results 9YM BioSciences reports second quarter 2010 operational and financial results 10YM BioSciences reports second quarter 2010 operational and financial results 11YM BioSciences reports second quarter 2010 operational and financial results 12Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors 2
(Date:8/19/2014)... study that analyzed concentrations of African dust transported ... winter and spring. These research findings offer new ... quality impacts of African dust, including the climate ... occur from increased African dust emissions in the ... (UM) Rosenstiel School of Marine and Atmospheric Science ...
(Date:8/19/2014)... This news release is available in French . ... Stand: balancing the BENEFITS and RISKS of physical activity ... a stand on the promotion of childhood physical activity ... Applied Physiology, Nutrition, and Metabolism ( APNM ... of knowledge in the area of risk of physical ...
(Date:8/19/2014)... , August 19, 2014 ... / Digital Wallet Choices as latest developments, ad campaigns ... Inc. (NASDAQ: EBAY ), Amazon.com Inc. (NASDAQ: ... AAPL ), Google Inc. (NASDAQ: GOOG ) ... (OTCQB: NXTD) a biometric authentication company focused on the ...
Breaking Biology News(10 mins):Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7
... discovered that very small chemical changes to dietary flavonoids cause ... for their impact on the human immune system., Plants are ... an average leaf for example, produces around 20,000. Many ... are already known to have medicinal properties with effects on ...
... and government, industry and health professionals will gather in ... the research supporting the health benefits of mushrooms ... produce aisle and often thought of as a vegetable ... The Mushrooms and Health Summit, held at the ...
... cholesterol levels and reducing the risks of cardiovascular disease, but ... The FASEB Journal suggests that they may extend ... which telomeres shorten, a key factor in the natural aging ... of statins, as an anti-aging therapy. "By telomerase activation, ...
Cached Biology News:Little changes -- large effects 2World's scientists, researchers and nutrition experts convene to explore the benefits of mushrooms 2
...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
... Point Osmometer for 10 L sample. ... including pediatric, neonatal, geriatric, general adult, ... Calibration with 2 or 3 user-selected ... and software for statistical analysis and ...
Biology Products: